PLoS ONE (Jan 2016)

Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous Clearance.

  • Sabrina J Merat,
  • Richard Molenkamp,
  • Koen Wagner,
  • Sylvie M Koekkoek,
  • Dorien van de Berg,
  • Etsuko Yasuda,
  • Martino Böhne,
  • Yvonne B Claassen,
  • Bart P Grady,
  • Maria Prins,
  • Arjen Q Bakker,
  • Menno D de Jong,
  • Hergen Spits,
  • Janke Schinkel,
  • Tim Beaumont

DOI
https://doi.org/10.1371/journal.pone.0165047
Journal volume & issue
Vol. 11, no. 10
p. e0165047

Abstract

Read online

Hepatitis C virus (HCV) is world-wide a major cause of liver related morbidity and mortality. No vaccine is available to prevent HCV infection. To design an effective vaccine, understanding immunity against HCV is necessary. The memory B cell repertoire was characterized from an intravenous drug user who spontaneously cleared HCV infection 25 years ago. CD27+IgG+ memory B cells were immortalized using BCL6 and Bcl-xL. These immortalized B cells were used to study antibody-mediated immunity against the HCV E1E2 glycoproteins. Five E1E2 broadly reactive antibodies were isolated: 3 antibodies showed potent neutralization of genotype 1 to 4 using HCV pseudotyped particles, whereas the other 2 antibodies neutralized genotype 1, 2 and 3 or 1 and 2 only. All antibodies recognized non-linear epitopes on E2. Finally, except for antibody AT12-011, which recognized an epitope consisting of antigenic domain C /AR2 and AR5, all other four antibodies recognized epitope II and domain B. These data show that a subject, who spontaneously cleared HCV infection 25 years ago, still has circulating memory B cells that are able to secrete broadly neutralizing antibodies. Presence of such memory B cells strengthens the argument for undertaking the development of an HCV vaccine.